There is evidence that an aberrant tumour microenvironment (TME) facilitates cancer development, progression, and responses to treatment. While many of the mechanisms underlying the phenotype and cancer-promoting behaviour of the TME are unknown, epigenetic mechanisms in cancer cells and the TME are thought to play important roles. As a result, cancer profiling strategies for drug and biomarker development require a thorough understanding of both the epithelial tissue compartment and the TME. This review discusses recent advances in our understanding of how cancer epithelial cells interact with their microenvironment and how this knowledge can be exploited clinically.
INTRODUCTION
Breast cancer tissues contain genetic and epigenetic changes that result in altered epithelial cell structure and function. Epigenetic regulation is defined as any heritable modifications in gene expression and chromatin structure caused by alterations that do not involve the primary nucleotide sequence. 1, 2 Epigenetic changes include DNA methylation, post-translational modifications of histone proteins, nucleosomal positioning, incorporation of histone variants, and the action of non-coding RNAs [such as micro (mi)RNAs]. 3 The 'classical' epigenetic effect occurs when epigenetic silencing of one allele acts in concert with an inactivating mutation in the opposite allele, resulting in total allelic loss; for example, hypermethylation and deletion of the BRCA1 promoter in sporadic breast cancer. 4 The tumour microenvironment (TME) also represents an important source of epigenetic regulation of the epithelial compartment in breast cancer. As well as harbouring malignant cells, the TME contains cells of mesenchymal and haematopoietic origin and non-cellular components. 5 Cells of mesenchymal origin in the TME include fibroblasts, myofibroblasts, mesenchymal stem cells (MSCs), adipocytes, and endothelial cells, while cells of haematopoietic origin include lymphoid cells [T cells, B cells, and natural killer (NK) cells] and myeloid cells [macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs)]. The non-cellular component is the extracellular matrix (ECM) formed by the basement membrane and interstitial matrix (consisting of collagens, proteoglycans, and glycoproteins) ( Fig. 1 ).
The TME also has an important metabolic (pH, PO 2 , glucose, glutamine, lactate) and chemical (e.g., nitric oxide) environment. 6 This is further discussed by Simmons et al. in this issue. 7 Experimental modelling has shown that epigenetic cross-talk between cells in the TME drives the efficiency of cancer formation, the rate of cancer growth, the extent of invasion, the ability of cancers to metastasise, and their response to treatments. 8 
CANCER-ASSOCIATED FIBROBLASTS IN THE TME
What are cancer-associated fibroblasts?
Fibroblasts are generally the most abundant cell type in the TME. A subpopulation of fibroblasts known as cancerassociated fibroblasts (CAFs) is thought to be of critical importance in cancer initiation, progression, survival, metastasis, and invasion via the secretion of various growth factors, cytokines, and chemokines and the degradation of ECM proteins. 9, 10 The origins of CAFs in breast cancer stroma are diverse. 10 The vast majority are thought to arise from normal fibroblasts, and breast cancer cells are known to induce epigenetic changes in normal fibroblasts that transform them into CAFs. For instance, Tyan et al. 11 showed that breast cancer cells can induce hepatocyte growth factor (HGF) secretion by CAFs to enhance tumorigenesis and that when normal fibroblasts were cultured with the breast cancer cell line MDA-MB-231 they secreted HGF and adopted a CAF phenotype. In another example, the MCF-7 breast cancer cell line was found to reduce caveolin-1 (Cav-1) expression (a CAF biomarker) in normal fibroblasts, resulting in phenotype switching to CAFs and increased expression of CAF-associated markers. 12 CAFs also arise when epithelial cells undergo epithelialmesenchymal transition (EMT), from bone marrow-derived stem cells that have undergone EMT, or from transdifferentiated breast tissue cells such as pericytes, adipocytes, or smooth muscle cells (Fig. 2) . 13, 14 The CAF profile differs depending on the TME and breast cancer subtype. In general, CAFs highly express a-SMA, p53, podoplanin, CD10, fibroblast activation protein (FAP), matrix metalloproteinases (MMPs), tenascin-C, and platelet-derived growth factor (PDGFRa/b) and lose Cav-1 expression. 10, 12 Cytoskeletonand integrin signalling-associated genes are up-regulated in HER2+ breast cancers compared to triple-negative breast cancers. 15 However, a universal CAF 'signature' has so far proven elusive. 10 The gene expression profiles of fibroblasts from women without breast cancer have been compared to those from women with breast cancer. 16 Many genes are up-regulated in CAFs compared to normal fibroblasts including growth factors [fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), transforming growth factor beta (TGF-b), and stromal cell-derived factor 1 (SDF-1)], cytokines [granulocyte macrophage colony-stimulating factor (GM-CSF), effector cell protease receptor 1 (EPR-1)], oncoproteins (K-ras), regulators of gene expression (nuclear-encoded mitochondrial elongation factor Ts, ribosomal protein S12, and spliceosomeassociated protein SAP 145), and a variety of other genes associated with the cell cycle, cell-cell interactions, and cellcell communication. Many of these gene products are proinvasive and pro-metastatic. 10, 17 Breast cancer CAFs also show aberrations in DNA methylation, histone modifications, and dysregulated miRNAs. 18 While all DNA is coated with methyl moieties, the DNA methylation pattern is regulated by an independent enzymatic process catalysed by DNA methyltransferases (DNMTs). In terms of DNA methylation, the DNA methylation profiles of 143 human breast tumours showed significant differences in HER2 expression and DNA methylation Fig. 1 Components of the tumour microenvironment (TME). The TME is a complex mixture of not only carcinoma cells but also many cells of different lineages and extra-cellular material. The cellular component includes cells of mesenchymal origin [fibroblasts, cancer-associated fibroblasts (CAFs), myofibroblasts, mesenchymal stem cells (MSCs), adipocytes, and endothelial cells] and those of haematopoietic origin: lymphoid cells [T cells, B cells, and natural killer (NK) cells] and myeloid cells (macrophages), neutrophils, and myeloid-derived suppressor cells (MDSCs). The non-cellular component is the extracellular matrix (ECM). The TME is an important epigenetic regulator of the epithelial compartment in breast cancer that ultimately influences the cancer phenotype. Fig. 2 Potential origins of cancer-associated fibroblasts (CAFs). There are multiple sources of CAFs, with the vast majority arising from phenotypic switching of normal fibroblasts under the influence of epigenetic signalling from breast cancer cells (non-stem-like carcinoma cells and cancer stem cells). However, CAFs can also arise from epithelial-mesenchymal transition (epithelial cells), transdifferentiated pericytes, adipocytes, or smooth muscle cells, and bone marrow-derived stem cells. These TMEinfluenced pathways induce epigenetic changes that promote a CAF profile. of five genes, three of which were also methylated in the tumour stroma as well as the cancer cells. 19 Furthermore, methylation-specific digital karyotyping revealed epigenetic alterations in stromal fibroblasts as well as epithelial and myoepithelial cells in normal breast tissues compared to in situ and invasive carcinomas. 18 DNA is normally wrapped around histones, thereby providing another important mechanism of gene regulation. Loss of histone deacetylase 1 (HDAC1) expression has been shown to increase osteopontin glycoprotein expression within the stromal compartment of invasive breast cancers, which then activates CAFs to promote tumour growth in vivo. 20 MicroRNAs (miRNAs) are a class of short noncoding regulatory RNAs involved in stem cell maintenance, developmental programming, cell fate specification, and various pathologies, not least cancer. Depending on the protein targeted, miRNAs can act as either oncogenes or tumour suppressors. miRNAs have been shown to be dysregulated in breast CAFs; in particular, miR-200s are down-regulated in activated CAFs in breast cancer tissues. 21 
Breast CAFs can induce EMT in breast cancer cells and the cancer stem cell phenotype
The process of EMT confers mesenchymal properties on epithelial cells that are closely associated with the acquisition of aggressive traits seen in the cancer stem cell (CSC) phenotype. 22 Furthermore, such CSCs have been shown to resist standard anticancer therapies. 23 Several studies have shown that breast CAFs can induce an EMT signature (including increased vimentin expression and decreased Ecadherin expression) in breast cancer cells ( Fig. 3 ). [23] [24] [25] For example, non-CSCs [also known as non stem-like cancer cells (NSCs)] derived from human mammary basal epithelial cells (HMECs) maintain the ZEB1 promoter, a key regulator of EMT transition, in a bivalent chromatin configuration. 26 Bivalency in this context refers to chromatin existing in a repressed state but poised for rapid transcriptional activation in response to signalling cues that favour differentiation; this enables them to switch to a stem cell-like state. In the bivalent state, the ZEB1 promoter is marked with both active (H3K4me3) and repressive (H3K27me3) histones. In response to microenvironmental signals such as TGF-b, a well-known EMT inducer, released by CAFs, the ZEB1 promoter converts to an active chromatin configuration (with loss of H3K27me3), ZEB1 transcription increases, and non-CSCs enter the CSC state. These CSCs can self-renew and drive tumorigenesis. Breast CSCs display a CD44+/CD24cell surface marker profile and are also known to form a subpopulation of circulating tumour cells that might give rise to metastases. CAFs, through increased expression of the chemokine CCL2 via NOTCH1-STAT3 activation, have been shown to stimulate the CSC phenotype in breast cancer cells and inhibition of CCL2 in fibroblasts in xenograft models of breast cancer abrogates this tumorigenic effect. 27 De Marco et al. 28 recently showed that CAFs mediate the malignant phenotype and cancer aggressiveness through secretion of IL-1b into the TME and its consequent effect on breast cancer cells, as IL-1b drives a pro-tumorigenic inflammatory phenotype via the IL1R1 receptor on cancer cells. The G-protein oestrogen receptor (GPER) triggers upregulation of IL-1b and ILIR1 expression on CAFs and breast cancer cells, respectively, to promote breast cancer cell migration and invasion. 28 The relationship between EMT and epithelial CSCs indicates that EMT is thus particularly dangerous since, by imparting mesenchymal traits to carcinoma cells, EMT can generate properties associated with high-grade malignancy including motility, invasion, resistance to apoptosis, and metastasis. 22 CAFs and their effect on other components of the microenvironment CAFs are also known to mediate a tumour-enhancing inflammatory profile driven by NF-kB, which promotes angiogenesis and tumour growth via the release of growth factors (FGFs, HGF, TGF-b, SDF1), cytokines (CXCL12, IL-6), and hormones (such as oestrogen) in the TME. 29 -33 CAFs can attract immunosuppressive cells (for example, FOXP3 T cells and myeloid-derived suppressor cells) to the TME that inhibit T cell function and suppress adaptive immunity and natural killer cell function. 34, 35 CAF elimination Fig. 3 The role of cancer-associated fibroblasts (CAFs) in breast cancer epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. As shown in Fig. 2 , CSCs can induce epigenetic changes in fibroblasts to create a CAF phenotype. In this context, CAFs can induce a CSC profile in non-stem-like epithelial carcinoma cells through secretion of TGF-b and IL-1b into the tumour microenvironment (initiating EMT) and/or via increased expression of the chemokine CCL2 by CAFs interacting with carcinoma cells to induce transition of the non-stem-like carcinoma cells (NSCs) to a more mesenchymal state. Both of these pathways increase the acquisition of the mesenchymal CSC phenotype that favours breast cancer cell migration, invasion, and resistance to therapy. has been shown to reduce tumour-associated macrophages and myeloid-derived suppressor cell recruitment to tumours. 36 CAFs have also been shown to depress the Th1 immune response by suppressing Th1 cytokines and enhancing an immunosuppressive Th2 cytokine signature and tumour growth in CAF-knockout cancer metastasis models in vivo. 36 OTHER MESENCHYMAL COMPONENTS OF THE TME AND BREAST CANCER Adipocytes and endothelial cells in the TME Other cells of mesenchymal origin in the TME include adipocytes and endothelial cells. The concept that adipocytes participate in cancer initiation, growth, and metastasis is now called 'adiponcosis'. 37 For example, the release of CCchemokine ligand 5 (CCL5) by adipocytes has been shown to promote the motility and invasion of triple-negative breast cancer cells. 38 The secretion of factors such as leptin and interleukin 6 (IL-6) by adipocytes has been shown to be important in inducing breast cancer cell EMT and activating CSC pathways. 39 Furthermore, adipocytes have been shown in vitro and in vivo to participate in a highly complex cycle whereby breast cancer cells modify the phenotype of peritumoral adipocytes that in turn modify the cancer cell phenotype to promote cancer progression. 40 In addition to the accepted roles of tumour blood and lymphatic vessels as conduits for blood supply and tumour dissemination, these vessels have also been shown to play an important role in cancer cell crosstalk via molecules secreted by the blood (BEC) and lymphatic (LEC) endothelial cells (also called angiocrine and lymphangiocrine factors). BECcancer cell crosstalk can induce stem cell-like properties and EMT in cancer cells similar to CAFs. 41 Lee et al. 42 showed that triple-negative breast tumours induced LECs to secrete CCL5, which recruits CCR5-expressing cancer cells into the lymphatic system, thereby promoting lymph node metastasis.
Haematopoietic cells of the TME
The cells of haematopoietic origin in the TME include lymphoid cells (T cells, B cells, and NK cells) and myeloid cells (macrophages, neutrophils, and MDSCs). A detailed discussion of the role of tumour-infiltrating lymphocytes is the subject of a number of detailed reviews including in this edition and will not be discussed further. 43, 44 MDSCs are a heterogeneous population of immature myeloid cells that inhibit innate and adaptive immunity and suppress various immune cells such as T cells, dendritic cells, and NK cells and stimulate immune modulators such as Th2 T cells, T regulatory cells (Treg), and tumour-associated macrophages (TAMs). Increased MDSCs are closely correlated with increased tumour burden and the duration of breast cancer. 45 NK cells are a major component of the antitumor immune response and are involved in controlling tumour progression and metastasis in animal models. Mamessier et al. 46 showed that NK cell dysfunction causes human breast cancer progression. Breast cancer cells appear to alter NK cell function by modulating their surface receptors, and several stromaderived factors including TGF-b1 in the TME are involved in a tumour-induced reduction in normal NK cell function. 46 The ECM of the TME The ECM constitutes the non-cellular component of the TME and includes the basement membrane and interstitial matrix (consisting of collagens, proteoglycans, and glycoproteins). There is good evidence to suggest that proteoglycan/glycosaminoglycan expression levels and fine structures are involved in breast cancer growth, invasion, and metastasis. For example, the proteoglycan versican has been shown to stimulate mesenchymal-epithelial transition (MET) and increase breast cancer cell proliferation at metastatic sites. 47 DNA methylation also plays an important role in regulating collagens in cancer. 48 Chernov et al. 49 showed in MCF-7 breast cancer cells that certain collagen genes are epigenetically silenced by H3K27me3 repression, which changes the ECM composition to an invasion-promoting collagenenriched matrix. 49 The roles of various elements of the TME and their role in breast cancer are summarised in Fig. 4 .
CONTRIBUTION OF THE TME TO METASTASIS IN BREAST CANCER
Metastasis is an inefficient process. For most breast cancers only a minority of cancer cells successfully spread, colonise and grow at a distant site. 50 Metastasis is also dependent on the metastatic niche, which describes the specialised microenvironment that supports metastatic events and the environment at distant metastatic sites. 51 The metastatic niche model proposes two mechanisms by which successful metastasis might occur: through either a pre-existing niche or an induced metastatic niche. A pre-existing niche is a site that supports a pre-existing normal, specific physiological function that is then co-opted or hijacked by a metastatic cancer cell to aid its survival in the new TME such as within bone marrow. 52 In contrast, an induced niche is present when there have been changes to the nature of the microenvironment's ECM and component cells that are permissive to colonisation by metastatic cells. 52, 53 The TME also plays a critical role in regulating metastatic events in breast cancer. 52, 54, 55 Metastasis is not a single event but rather a complex series of events that includes the invasive tumour cell growth, ECM degradation, and invasion into the lymph or circulatory system. As noted above, tumour cells must undergo EMT to acquire an invasive and mesenchymal phenotype, and CAFs-a primary component of the breast cancer stroma-are significant mediators of EMT and metastasis. 56 However, this is not their sole function, as CAFs can also enhance invasion through active degradation of the ECM via a diverse array of mediators including upregulation of palladin (a cytoskeletal protein) and proteolytic enzymes. 57 CAFs can also play a direct role in cancer metastasis by leading the actual invasion and metastasis of tumour cells from the site of the primary tumour. 58 The niche colonised by cancer cells is an important part of the metastatic process. The ability of metastases to thrive at distant sites requires tumour cells to adapt to new and often dramatically different microenvironments. 59 Work by Malanchi et al. 54 demonstrated in a breast cancer model that POSTN is a critical mediator expressed in primary tumour stroma and that CSCs migrating to distant sites also need to induce stromal POSTN so that the tumour cells can colonise the new site. In this respect, the invading tumour cells alter the new microenvironment to be more receptive to metastatic colonisation. 54 Zhang et al. 55 recently illustrated an elegant example of tumour cell adaptation to a new TME in brain metastasis, with tumour cells losing PTEN expression after metastatic invasion of the brain but not other tissues and organs. It was proposed that extracellular vesicles (EVs) containing PTEN-blocking microRNAs may have mediated this knockdown effect. EVs comprise a diverse range of structures of different cellular origin and highly variable 'cargo' and include exosomes, microvesicles, and large oncosomes, 60 all of which can influence the TME. EVs can reprogram cancer cell metabolism, mediate therapeutic drug interactions, and are implicated in driving the transformation of fibroblasts and other TME cells to a CAF phenotype. [61] [62] [63] EVs can in turn enhance the metastatic potential of the tumour such as up-regulating MMP-9 expression in melanoma cells and reprogramming cancer cells with enhanced metastatic potential. 64 Le et al. 65 showed that EVs containing miR-200 can alter gene programming and promote MET. Tumour metastasis is enhanced by the mesenchymal phenotype; however in many tumours, including breast cancer, invading cells require epithelial traits to colonise other sites. miR-200 can confer strong metastatic potential to either adjacent cells or even tumour cells at distant sites through this re-programming. 65 
THE TME AND THERAPEUTIC RESISTANCE IN BREAST CANCER
Despite significant improvements in outcomes for breast cancer patients over the last 20 years, drug resistance and tumour recurrences occur. The TME, and specifically CAFs, are implicated in breast cancer resistance to therapy. 14 Several authors have shown that CAFs play a significant role in tamoxifen resistance through activation of the PI3K/ AKT and MAPK/ERK pathways and induction of the oestrogen receptor (ER) via the G protein-coupled ER to promote proliferation and progression of breast cancer cells. [66] [67] [68] Furthermore, Yuan et al. 69 demonstrated that the G protein-coupled ER GFR/ERK pathway increases b1integrin expression to contribute to CAF-associated EMT, invasion, and tamoxifen resistance in MCF-7 breast cancer cells. 69 Mao et al. 70 recently demonstrated that CAFs can render HER2+ breast cancer cells resistant to trastuzumab via IL-6 and the activation of multiple pathways including NF-kB, JAK/STAT3, and PI3K/AKT. 70 Farmer et al. 71 demonstrated that very desmoplastic stroma in breast cancer produces a stromal gene expression that predicts resistance to pre-operative chemotherapy. 71 The TME, and in particular the CAFs and immune cells, are also thought to play a role in radiotherapy resistance. 72 As various immunotherapies are introduced in breast cancer management, it is likely that both intrinsic but acquired therapeutic resistance will occur in the TME as reported in other cancers. 73 
THERAPEUTIC TARGETING OF THE TME USING EPIGENETIC DRUGS
The current standard treatment for breast cancer includes surgery, radiotherapy, chemotherapy and hormone therapy. The treatment given largely depends on the pathological characteristics of the breast cancer, the clinical stage of disease, and the age and general health of the patient. One of the potentially most attractive new therapies is targeting epigenetic inheritance because, in contrast to DNA mutations, these defects are passively inherited and thus must be actively maintained because they are reversible. Re-expression of genes epigenetically inactivated can suppress the disease state or sensitise to specific therapies. Small molecules that reverse epigenetic inactivation, so-called 'epi-drugs', are now undergoing clinical trials. To date, most epi-drug studies have focused on the direct treatment of the epithelial cell compartment rather than the TME. The best-studied Fig. 4 The various elements of the tumour microenvironment (TME) and their role in breast cancer. Breast non-stem-like cancer cells (NSCs) can, through paracrine signalling, inhibit the expression of caveolin-1 (CAV-1) in normal fibroblasts to promote a shift to a cancer-associated fibroblast (CAF) signature. The CAFs then increase expression of a variety of mediators that enhance tumorigenesis (coloured balls: red = HGF, blue = TGFb, orange = CCL2, green = IL6, yellow = IL1b, purple = SDF-1, black = CXCL12). This drives EMT and induces the non-stem-like cancer cell ZEB1 promoter to lose its tri-methylation on H3K27 (inactive mark red balls) and retain its active mark (green balls) H3K4me3, resulting in increasing chromatin accessibility of ZEB1 and transcription and allowing entry to the CSC signature that enhances invasion, metastasis, and resistance to therapy. The new CSC can in turn induce the formation of more CAF signature cells, resulting in feedback that increases overall tumour malignancy. In addition to this pathway, CAFs can also arise from endothelial cell EMT and other transdifferentiated cells (blue square cells). Adipocytes are also involved in this TME regulation (a process known as adiponcosis), contributing to tumorigenesis via EMT differentiation into CAFs to enhance cancer growth, survival, and aggressiveness through the secretion of IL6 (pink balls) and CCL5 (light blue balls). epigenetic drugs are the histone modifiers. Histones are modified by histone-modifying enzymes that add or remove covalent moieties to histone proteins. 74 Among these, histone acetyl transferases (HATs) act as 'writers' that transfer acetyl groups to lysine residues on histones to activate transcription, and histone deacetylases (HDACs) act as 'erasers' that remove acetyl groups to repress gene transcription. 75 The term 'HDAC inhibitors' refers to a group of compounds that target this latter mechanism, and these drugs have been tested in breast cancer clinical trials. 76, 77 DNA methyltransferase (DNMT) inhibitors are another group of epigenetic drugs that have been shown to inhibit cell growth and work well in combination with HDAC inhibitors. Furthermore, some DNMT inhibitors have been shown to re-express functional ER in ER negative breast cancer cells in which the ER has been epigenetically silenced. 78 Both DNMT and HDAC inhibitors have been shown to re-express epigenetically silenced genes in breast cancer and improve patient outcomes; however, long-term efficacy is limited and very high doses are often required, suggesting that combination strategies to enhance responses are important. 76, 79 Epigenetic modifying agents have been shown to 'prime' the immune system, making combination therapy with immune modulators attractive. Kim et al. 80 showed that 5azacytidine (5-AZA; a DNA methyltransferase inhibitor) in combination with anti PD-1 and anti CTLA-4 monoclonal antibodies eradicated both primary and metastatic tumours in mice. 80 5-AZA has also been shown to up-regulate genes responsible for antigen processing and presenting [such as tumour-associated antigens, major histocompatibility complex proteins, co-stimulatory molecules (e.g., CD40, CD80, CD86, ICAM-1)] and death-inducing receptors that target cancer cells (e.g., FAS), causing a shift in the balance of immune inhibition towards immune activation. 81 Recent studies by our laboratory (Zafar et al. 82 and Boulding et al. 83 ) have identified potential new classes of epigenetic therapeutic targets (Fig. 5 ). While protein kinase C (PKCs) have long been recognised as cytoplasmic signalling proteins, we and others have shown that PKCs belong to an emerging class of kinases that have a dual function as epigenetic enzymes. [84] [85] [86] These chromatin-tethered kinases modulate chromatin structure to make it conducive for active transcription by two distinct mechanisms: (1) structural (as part of transcription complexes) and (2) enzymatic (by phosphorylating key nucleosome components, the basic unit of chromatin). 82 Our findings have shown that PKC-theta (PKC-q) is a signalling kinase that is specifically targeted to the nucleus to function as a transcriptional regulator by tethering to the epigenome; PKC-q is also a critical molecular mediator of CSC function. This nuclear kinase mediates crosstalk between extracellular signals and the epigenome in breast CSCs in response to TGF-b and inflammatory signals mediated via the NF-kB pathway in breast cancer. 82 In particular, our genome-wide PKC-q chromatin immunoprecipitation (ChIP)-sequencing analysis identified direct PKCq-dependent targets in CSCs, with well-established master CSC regulators represented in the target geneset. 82 This novel nuclear PKC-q epigenetic mechanism in human CSCs shows that active nuclear PKC-q is critical for mediating open/ permissive chromatin regulatory regions and is essential for the transcription of key CSC-enriched genes. Our findings show that targeting PKC-q with selective inhibitors such as C27 or siRNA abrogates breast CSCs. Furthermore, dualspecificity phosphatases (DUSPs), which dephosphorylate q to the chromatin template to recruit RNA polymerase II (RNA POL II) and subsequent transcription of CSC-inducible genes. In addition, together with PKC-q, DUSP activation has been shown to have a critical role in the dephosphorylation of P300 at serine 89, which can further activate H3K27 acetylation at CSC repressive gene enhancers. These key molecular mechanisms can be inhibited (see blue inhibitor boxes) by blocking the epigenetic kinase PKC-q [with compound 27 (C27), bisindolylmaleimide I (BIM), or PKC-q siRNA] or NF-kB (with Bay11-7082 or NF-kB p50/p65 siRNA) or DUSP1 (with NSC 95397, triptolide, or DUSP1 siRNA). (B) High resolution 3D image of a mesenchymal breast cancer cell, clearly displaying the nuclear bias of the epigenetic kinase PKC-q in this cell. threonine/serine and tyrosine residues on their substrates, are involved in EMT and breast CSC regulation and are induced during EMT in a PKC pathway signal-mediated EMT model. 83 Hence, given that CSCs mediate the transition to CAFs in breast cancer, we postulate that targeting this novel PKC-epigenetic axis may offer new therapeutic avenues to simultaneously eliminate CAFs and CSCs in breast cancer. Given the importance of TGF-b and NF-kB in CAF-mediated tumorigenesis, 29, 87 PKC-q may also have a direct epigenetic role in CAFs that needs to be elucidated. PKCs belong to a family of 11 isoforms (conventional, atypical, and novel), and the interplay between these kinases, CAFs, and CSCs also requires further investigation. It remains to be seen if therapeutic targeting of these enzymes will abrogate CAFs in breast cancer in vivo.
Therefore, many components of the TME, particularly those related to EMT activation in breast cancer cells and the possible entry of these cells into the CSC state, 5 could potentially be targeted for cancer prevention and treatment as part of epi-drug development. Treatments that normalise the stroma are also potentially powerful therapeutic strategies. 88 
CONCLUSIONS
This review highlights that research into breast cancer development, progression, and management can no longer focus solely on malignant breast epithelial cells but also needs to address the role of the TME both in the primary cancer and in metastases. The role of the TME now needs to be considered when assessing the impact of various treatments. In the future, pathologists may need to map specific epigenetic profiles of individual TME components as part of the prognostic and predictive work-up of an individual cancer and to guide precision therapy.
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